Requiring the Prescription Drug Monitoring Program to monitor the prescribing and dispensing of Gabapentin by all prescribers and dispensers in the State; and requiring the Maryland Department of Health to submit a report on whether Gabapentin should be added to the a controlled dangerous substances schedule to the Senate Finance Committee and the House Health and Government Operations Committee on or before December 31, 2019.
Bill File Type: Regular
Effective Date(s): June 1, 2019
( 21-2A-02 )
Last Updated: 2/3/2020 2:31 PM